

Otsuka has the pleasure of
inviting haematologists to a
webinar on



Treatment options for fragile AML patients

Thursday September 17th at 16.30-17.30

Agenda:

16.30 Welcome, Ivar Haukeland, Brand Manager,
Otsuka Pharma Scandinavia AB

Early Nordic experience with AML therapies,
Professor Bjørn Tore Gjertsen, Bergen

16.55 The evolving AML treatment landscape,
Professor Gail Roboz, New York.

17.20 Questions and discussion, lead by
Professor Bjørn Tore Gjertsen, Bergen

**Register at the latest on
September 13, 2026
Scan the QR-kod to register to the
webinar**

BOKA



Warm welcome,

Helena Arlov-Sjögren

Helena.arlov-sjogren@otsuka.se

Key Account Manager

Otsuka Pharma Scandinavia AB



Gail J. Roboz, MD, William S. Paley Professor of Medicine Director, Clinical and Translational Leukemia Programs Weill Cornell Medicine in New York, USA. Dr. Roboz is an internationally recognized expert in developmental therapeutics and novel clinical trials for acute leukemias, myelodysplastic syndromes, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and co-chairs the clinical committee of the European Leukemia Net (ELN) working group on measurable residual disease in acute myeloid leukemia. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.



Bjørn Tore Gjertsen, MD, PhD. is Professor of Hematology from 2007 at Department of Clinical Science at the University of Bergen, working as Research Chief and Consultant Hematologist at Helse Bergen Health Trust, developing early phase clinical trials at Haukeland University Hospital. In 2016 Gjertsen was appointed co-director for Centre for Cancer Biomarkers (CCBIO) Norwegian Centre of Excellence, University of Bergen. Dr. Gjertsen is a founding member and chair of the Norwegian AML Group and the Nordic AML Group, and is a member of EHA, ASH, ASCO, and the Nordic CML Study Group. Bjørn Tore Gjertsen is the founder and director of KG Jebsen Centre for Myeloid Blood Cancer established in 2024.